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Abstract
Aims: 22q11.2 deletion syndrome
(22q11.2DS) is a neurogenetic condi-
tion associated with an increased risk
of developing schizophrenia. Previ-
ous studies have shown that negative
symptoms represent themost specific
clinical characteristic of psychosis in
22q11.2DS and are strongly associ-
ated with outcome. However, the
psychological mechanisms associ-
ated with these symptoms in this
population are poorly understood.
In accordance with recent concep-
tualizations in the field of schizo-
phrenia, the present study aims at
investigating whether negative symp-
toms are associated with the presence
of negative performance beliefs and
cognitive deficits.
Methods: Thirty-five participants
with 22q11.2DS and 24 typically
developing individuals aged between
11 and 24 years were included in
the study. Self-reported schizotypal
symptoms (cognitive-perceptual,
paranoid, negative and disorganiza-
tion symptoms) and dysfunctional
beliefs (negative performance beliefs
and need for approval) were assessed.
Measures of processing speed, verbal
memory, working memory, executive
functioning and face recognitionwere
also extracted from a broad cognitive
evaluation protocol.
Results: Adolescents with 22q11.2DS
reported significantly higher score
on the negative dimension of the
Schizotypal Personality Question-
naire than controls, even when con-
trolling for the influence of anxiety/
depression and intellectual func-
tioning. Negative and paranoid symp-
toms were associated with the sever-
ity of negative performance beliefs
and lower face recognition abilities.
Mediation analyses revealed that
negative performance beliefs signifi-
cantly mediated the association
between face recognition and
negative/paranoid symptoms.
Conclusions: These findings suggest
that negative performance beliefs and
basic social cognitivemechanisms are
associated with negative and para-
noid symptoms in individuals with
22q11.2DS. Implications for interven-
tion are discussed in this article.
Key words: 22q11.2 deletion syndrome, face recognition, negative per-
formance belief, negative symptom.
INTRODUCTION
22q11.2 deletion syndrome (22q11.2DS) is a
neurogenetic condition affecting 1 in 4000 live
births and associated with a wide range of physical
and behavioural problems and intellectual disabil-
ity.1 In particular, 22q11.2DS is one of the highest
known risk factors for the development of
schizophrenia, as 30–40% of adults meet formal
diagnostic criteria for a schizophrenia spectrum
disorder.2–4 Using clinical interviews that enable to
examine symptoms in a dimensional perspective,
several studies have found that positive and nega-
tive symptoms of moderate to severe intensity are
even more frequent. Indeed, they are encountered
by 50% and 80% of adolescents and young adults
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with 22q11.2DS, respectively.5–10 However, to the
best of our knowledge, very few studies have
exploredwhether individuals with 22q11.2DS report
higher positive and negative symptom scores when
assessed with self-reported measures, such as the
Schizotypal Personality Questionnaire (SPQ).11 In a
previous study using the SPQ, adolescents with
22q11.2DS reported significantly more negative
symptoms (but not positive or disorganization
symptoms) than typically developing controls.12
Altogether, self-reports and interview-based tech-
niques indicate that negative symptoms are particu-
larly frequent and severe in adolescents and young
adults with 22q11.2DS. Furthermore, two independ-
ent studies have shown that negative symptoms
represent the most specific clinical characteristic of
psychosis in 22q11.2DS.5,9
The fact that negative symptoms are an integral
part of the clinical profile in 22q11.2DS conveys
important implications. In accordance with
findings from the schizophrenia literature, negative
symptoms in 22q11.2DS are associated with decrea-
sed social and occupational functioning.8,9,13–16
Furthermore, pharmacological treatments and
classical cognitive-behaviour therapy (CBT) in
patients with schizophrenia typically show modest
improvements on negative symptoms.17,18 This
stresses the need to develop psychosocial interven-
tions that specifically target negative symptoms
and are adapted for patients with 22q11.2DS.
However, the psychological factors associated with
negative symptoms in this population are poorly
understood.
Research in the field of schizophrenia has shown
that negative symptoms aremore strongly related to
cognitive impairments than positive symptoms.19,20
In particular, the severity of negative symptoms
has been associated with diminished processing
speed,21,22 working memory,23,24 verbal memory,22
executive functioning20,25 and social cognition.26
Furthermore, a previous study indicated that indi-
viduals with 22q11.2DS and predominant negative
symptoms were characterized by decreased pro-
cessing speed and memory for social information.9
This suggests that impairments in these specific
cognitive domains may be related to the develop-
ment and maintenance of negative symptoms in
22q11.2DS.
Furthermore, the cognitive model of negative
symptoms formulated by Rector et al. puts forward
the role of dysfunctional cognitive appraisals and
beliefs in the development of negative symptoms in
schizophrenia.27 Individuals who will develop
schizophrenia later in life are more likely to have
subtle cognitive deficits during childhood and ado-
lescence,28 which increases the risk of recurrent
experiences of failure during development.29
According to Rector et al., these negative experi-
ences may trigger a set of dysfunctional beliefs,
especially negative performance beliefs (i.e. exces-
sively negative meanings for perceived failure), that
are thought to underlie the onset of negative symp-
toms.27 Within this framework, negative symptoms
are viewed as a protective strategy against expected
experiences of failure in future goal-directed activ-
ities. Based on this model, other dysfunctional
beliefs (e.g. excessive need for approval) are not
conceptually related to the development of negative
symptoms. This model has been tested in different
populations, including individuals with or at risk for
schizophrenia. Significant correlations between
negative performance beliefs and the severity of
negative symptoms were consistently reported,
even when the effect of other variables, such as
depression level, was controlled for.30–34 Importantly,
Grant and Beck observed that negative performance
beliefs significantly mediated the association
between low cognitive performance and the severity
of negative symptoms.31
The overarching aim of this study is to explore the
associations between negative symptoms, cognition
and dysfunctional beliefs in 22q11.2DS. To achieve
this, we first compared SPQ dimensions (i.e.
cognitive-perceptual, paranoid, negative and disor-
ganization) between participants with 22q11.2DS
and typically developing controls. We expected that
participants with 22q11.2DS would report signifi-
cantly higher scores on the four SPQ dimensions
than the control group. We then examined whether
cognitive deficits and negative performance beliefs
were associatedwith the clinical expression of nega-
tive symptoms in participants with 22q11.2DS. We
made the hypothesis that negative symptomswould
be specifically associated with the severity of nega-
tive performance beliefs (but not with other dys-
functional beliefs). Need for approval was therefore
used as a ‘control’ variable. Finally, we explored
whether specific cognitive deficits were associated
with negative performance beliefs and negative
symptoms, and tested for potential mediation
effects.
METHODS
Participants
Thirty-five participants with 22q11.2DS and 24 typi-
cally developing individuals aged between 11 and 24
years were included in the study (see Table 1). Both
groups were matched for age (F(1, 57) = −1.061,
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P = 0.293) and gender (χ = 0.578, P = 0.447). Seven-
teen (48.57%) participants with 22q11.2DS were
receiving psychotropic medication at the time of
testing: 11 were on methylphenidate, 7 on antide-
pressant medication, 3 on antipsychotics, 1 on
anxiolytics, and 2 on mood stabilizer.
Individuals with 22q11.2DS were recruited
throughadvertisements inpatientassociationnews-
letters. The presence of a 22q11.2microdeletion was
confirmed using quantitative fluorescent polymer-
ase chain reaction. Typically developing individuals
were recruitedamong the siblingsof theparticipants
with 22q11.2DS (N = 13; 54.20%)or through the local
school system (N = 11; 45.80%). Strict exclusion cri-
teria were used to recruit the control group. Partici-
pants were excluded if theymet one of the following
criteria: any history of neurological problems or
prematurity, history of any type of psychological
treatment or speech therapy, history of learning dif-
ficulties, YSR/ASR (Youth Self-Report/Adult Self-
Report) total problem score in the clinical range
(t-score ≥ 64). Written informed consent was
obtained from participants and their parents under
protocols approved by the Institutional Review
Boardof theDepartment of Psychiatry at theUniver-
sity of Geneva Medical School.
Materials
Self-reported questionnaires
All the participants completed the SPQ,11,35,36 a
74-item self-report assessing schizotypal experi-
ences. An original three-factor structure (cognitive-
perceptual, interpersonal and disorganization)
was proposed by Raine et al.11 More recently,
Stefanis et al. argued that a four-factor model
better accounted for the latent structure of the
SPQ.37 In the present article, we decided to use the
cognitive-perceptual, paranoid, negative and disor-
ganization dimensions as measures of self-reported
schizotypal symptoms.37
Participants also completed the Dysfunctional
Attitude Scale-Form A (DAS), a 40-item self-report
assessing dysfunctional beliefs.38,39 Factor analyses
on theDAS have yieldedmixed findings, with results
ranging between one and four dimensions.40,41
However, two dimensions relating to negative per-
formance beliefs (e.g. ‘If I fail partly, it is as bad as
being a complete failure’) and need for approval
(e.g. ‘My value as a person depends greatly on what
others think of me’) were more consistently
reported.We used the negative performance beliefs
TABLE 1. Descriptive statistics for the 22q11.2DS and the control groups. If not otherwise specified, mean (SD) is displayed. Effect size
and P-values after controlling for the influence of anxiety-depression and full-scale IQ are displayed in italic
22q11.2DS Controls Effect size P
(N = 35) (N = 24) (ηp2)
Age 18.06 (3.40) 17.19 (2.60) 0.019 NS
Gender (% females) 60.00% 50.00% – NS
Any psychotic disorder† (% present) 8.57% NA – NA
Any anxiety disorder‡ (% present) 37.14% NA – NA
Any mood disorder§ (% present) 11.43% NA – NA
SPQ cognitive-perceptual 2.14 (2.75) 0.88 (1.19) 0.073/0.005 0.038/NS
SPQ paranoid 7.06 (5.31) 3.17 (4.18) 0.137/0.061 0.004/0.065
SPQ negative 11.00 (6.80) 4.38 (5.21) 0.221/0.133 <0.001/0.005
SPQ disorganization 5.20 (3.74) 2.67 (3.86) 0.100/0.059 0.014/0.069
DAS negative performance beliefs 55.66 (23.40) 51.04 (13.27) 0.013 NS
DAS need for approval 24.26 (8.74) 26.88 (7.63) 0.024 NS
PSI z-score −0.53 (0.87) 0.78 (0.59) 0.420 <0.001
Letter-Number Sequencing z-score −0.51 (0.78) 0.74 (0.80) 0.385 <0.001
Immediate Paired Associates z-score −0.43 (0.85) 0.62 (0.88) 0.272 <0.001
Verbal Fluency Animal z-score −0.39 (0.78) 0.57 (1.02) 0.226 <0.001
BFRT z-score −0.62 (0.67) 0.90 (0.65) 0.569 <0.001
†Schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder and psychotic disorder not otherwise
specified.
‡Simple phobia, specific phobia, generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety disorder
(only assessed in participants <18 years) and panic disorder (only assessed in participants ≥18 years).
§Major depressive disorder, dysthymia and bipolar disorder.
BFRT, Benton Faces Recognition Test; DAS, Dysfunctional Attitude Scale; NA, not applicable; NS, not significant; PSI, Processing Speed Index; SPQ,
Schizotypal Personality Questionnaire.
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and need for approval dimensions defined by
Chioqueta and Stiles as measures of dysfunctional
beliefs.40 Finally, all participants completed the YSR
or the ASR.42,43 The anxiety-depression t-score was
used as a self-reported measure of anxiety and
depression.
Cognitive assessment
Full-scale IQ was obtained using the age appropri-
ate version of the Wechsler Intelligence Scale, 3rd
edition.44,45 In addition, measures of five cognitive
skills were extracted from a broad cognitive evalu-
ation protocol: processing speed, verbal memory,
working memory, executive functioning and face
recognition. Processing speed was assessed using
the Processing Speed Index from theWechsler Intel-
ligence Scale for Children, 3rd edition (WISC-III) or
Wechsler Adult Intelligence Scale, 3rd edition
(WAIS-III). Verbal memory was assessed using the
Verbal Paired Associates Immediate standard score
from the Children Memory Scale or the Wechsler
Memory Scale.46,47 Working memory was assessed
using the Letter-Number Sequencing standard
score from the Wechsler Intelligence Scale for Chil-
dren, 4th edition (WISC-IV)48 or the WAIS-III.
Executing functioning was assessed using the
number of total correct answers on the Semantic
Verbal Fluency Test (animal naming). Finally, face
recognition was assessed using the Benton Facial
Recognition Test (BFRT).49 Scores were converted
into z-scores for more direct comparisons.
Statistical analyses
Group comparisons between individuals with
22q11.2DS and controls were performed using
anovas. ancovas were also performed to control
the effect of general intellectual functioning and
anxiety/depression on the observed results.
Pearson’s correlations were conducted to examine
the associations between schizotypal symptoms
and dysfunctional beliefs in individuals with
22q11.2DS. Partial correlations were conducted to
control for the influence of anxiety/depression.
Pearson’s correlations were also used to examine
whether cognitive functioning was associated with
dysfunctional beliefs and schizotypal symptoms. If
three variables were shown to have reciprocal links
between them, post hoc mediation analyses were
conducted using the Sobel test.
All the analyses were performed using SPSS
version 21, except for mediation analyses that were
performed using the Quantpsy online interactive
tool.50
RESULTS
Group comparisons
A 2 × 4 manova revealed a significant group differ-
ence on SPQ scores (F(4, 54) = 4.157, P = 0.005;
Wilks’ lambda = 0.765, ηp2 = 0.235), indicating sig-
nificantly higher levels of schizotypal symptoms
in the 22q11.2DS group. Specifically, participants
with 22q11.2DS showed higher scores on the
cognitive-perceptual (F(1, 57) = 4.515, P = 0.038),
paranoid (F(1, 57) = 9.037, P = 0.004), negative
(F(1, 57) = 16.208, P < 0.001) and disorganization
(F(1, 57) = 6.360, P = 0.014) dimensions of the SPQ
(see Table 1).
After covariating for anxiety/depression (YSR/
ASR anxiety-depression t-score) and general intel-
lectual functioning (full-scale IQ), the multivariate
test approached significance (F(4, 52) = 2.511,
P = 0.053; Wilks’ lambda = 0.838, ηp2 = 0.162). The
analysis of each individual variable revealed a sig-
nificant group difference for the negative dimension
of the SPQ (F(1, 55) = 8.468, P = 0.005) only (see
Table 1).
The two groups did not differ on the severity of
negative performance beliefs (F(1, 57) = 0.763,
P = 0.386) or need for approval (F(1, 57) = 1.414,
P = 0.239). When the influence of anxiety/
depression and general intellectual functioning was
controlled for, participants with 22q11.2DS tended
to experience more negative performance beliefs
(F(1, 55) = 3.825, P = 0.056).
Finally, participants with 22q11.2DS had signifi-
cantly lower scores than the control group on the
five cognitive domains (all P < 0.001).
Associations between dysfunctional beliefs and
schizotypal symptoms in 22q11.2DS
In participants with 22q11.2DS, negative perfor-
mance beliefs were significantly associated with the
paranoid (r = 0.647, P < 0.001), negative (r = 0.572,
P < 0.001) and disorganization (r = 0.396, P = 0.018)
dimensions of the SPQ, but not with the cognitive-
perceptual dimension (r = 0.264, P = 0.126). Need
for approval was associated with the severity of
paranoid (r = 0.463, P = 0.005) and negative symp-
toms (r = 0.411, P = 0.014). Partial correlations con-
trolling for the YSR/ASR anxiety-depression t-score
did not change the results, except that the correla-
tion between negative performance beliefs and dis-
organization symptoms was no longer significant
(r = 0.257, P = 0.143) (see Figure 1).
Multiple linear regression models with negative
performance beliefs and need for approval as
Negative symptoms in 22q11.2DS
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independent variables were conducted to predict
the SPQparanoid and negative scores. In both cases,
the severity of negative performance beliefs was the
only significant predictor (see Table 2).
Associations between cognitive functioning,
dysfunctional beliefs and symptoms
in 22q11.2DS
Associations between dysfunctional beliefs and
cognitive functioning were examined using
Pearson’s correlations. This revealed that the sever-
ity of negative performance beliefs was significantly
associated with the BFRT total score (r = −0.388,
P = 0.021). The remaining cognitive domains were
not associated with negative performance beliefs.
Need for approval was only positively associated
with the Semantic Verbal Fluency Test (animal
naming) (r = 0.360, P = 0.033).
Associations between cognitive functioning and
the four SPQ dimensions were also examined using
Pearson’s correlations. The paired associates
immediate standard score was significantly associ-
ated with the disorganization (r = −0.464, P = 0.005)
and cognitive-perceptual (r = −0.369, P = 0.029)
dimensions. The BFRT total score was significantly
associated with the paranoid (r = −0.362, P = 0.022)
and marginally with the negative (r = −0.321,
P = 0.060) dimensions.
Mediation analyses
Because of the reciprocal associations between
negative performance beliefs, the BFRT total score
and paranoid/negative symptoms, we tested for
potential mediation effect using the Sobel test. In
accordance with the results from Grant and Beck,
we examined whether negative performance beliefs
(mediator) mediated the association between face
recognition (independent variable (IV): BFRT total
score) and symptoms (dependant variable (DV):
paranoid/negative symptoms). Specifically, the
Sobel test examines whether the indirect effect of
the IV on the DV via the mediator is significantly
different from zero. In both cases, the Sobel test was
FIGURE 1. Correlations between negative performance beliefs
and (a) paranoid symptoms or (b) negative symptoms in partici-
pants with 22q11.2DS.
TABLE 2. Multiple regression models for determining the predictive value of dysfunctional beliefs on the severity of paranoid and
negative symptoms in 22q11.2DS
Models Model Coefficients
Independent variables (significant
variables are displayed in bold)
R2 F(2, 34) b SE b β t p
Model 1 (DV: SPQ paranoid dimension) 0.420 11.567
DAS negative performance beliefs 0.155 0.046 0.684 3.366 0.002
DAS need for approval −0.030 0.123 −0.050 −0.244 0.808
Model 2 (DV: SPQ negative dimension) 0.328 7.797
DAS negative performance beliefs 0.175 0.064 0.602 2.751 0.010
DAS need for approval −0.031 0.170 −0.040 −0.183 0.856
DAS, Dysfunctional Attitude Scale; DV, dependent variable; SPQ, Schizotypal Personality Questionnaire.
M. Schneider et al.
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statistically significant (paranoid symptoms as DV:
z = −2.080, P = 0.037; negative symptoms as DV:
z = −1.970, P = 0.049). The mediations were consid-
ered as total because the direct associations
between the IV and the DV were no longer signifi-
cant after the mediator’s inclusion.
DISCUSSION
The aim of this study was to explore the associations
between negative symptoms, cognition and dys-
functional beliefs in 22q11.2DS.When the influence
of anxiety/depression and general intellectual func-
tioning was taken into account, participants with
22q11.2DS reported significantly higher scores on
the negative dimension of the SPQ compared to
their typically developing peers, whereas the
remaining dimensions did not significantly differ
between the two groups. Correlations within the
22q11.2DS group revealed that the severity of dys-
functional beliefs was associated with negative and
paranoid symptoms. Although both types of dys-
functional beliefs (negative performance beliefs and
need for approval) were correlated with negative
and paranoid symptoms, multiple regression analy-
ses indicated that negative performance beliefs
were the most important predictor. Paranoid and
negative symptoms, as well as negative perfor-
mance beliefs, were significantly associated with
lower face recognition scores. Mediation analyses
revealed that negative performance beliefs signifi-
cantly mediated the association between face rec-
ognition and paranoid/negative symptoms.
Adolescents and young adults with 22q11.2DS
reported significantly more positive (cognitive-
perceptual and paranoid symptoms) and disorgani-
zation symptoms than controls. Nevertheless, these
group differences were no longer significant after
controlling for the influence of anxiety/depression
and intellectual functioning. This suggests that dis-
turbed emotional processes and low intellectual
functioning influence the clinical expression of
positive and disorganization symptoms in the
context of the 22q11.2DS, which is consistent with
recent conceptualizations in the field of schizophre-
nia.51 On the opposite, the group difference for the
SPQ negative dimension remained statistically sig-
nificant even after controlling for these two vari-
ables. Furthermore, the effect size for the negative
dimensionwas twice as large as for the other dimen-
sions. These findings are consistent with previous
reports indicating that the severity of negative
symptoms is a clinical characteristic of
22q11.2DS.5,8,9 For this reason, we believe that a
better understanding of the cognitive mechanisms
associated with the onset andmaintenance of nega-
tive symptoms may ultimately help in the develop-
ment of intervention strategies. Indeed, reducing
the severity of negative symptoms seems crucial to
improve outcome in this population.8,9
Dysfunctional beliefs were investigated in the
present study, as their role was emphasized in
Rector et al.’s model of negative symptoms.27 In this
model, the presence of negative performance
beliefs plays a cardinal role whereas other dysfunc-
tional beliefs (e.g. excessive need for approval) are
not related to the development of negative symp-
toms. In the present study, participants with
22q11.2DS were not characterized by increased dys-
functional beliefs compared to the control group,
which contrasts with previous findings in individ-
uals with or at risk for schizophrenia.31,32 This indi-
cates some degree of heterogeneity within the
22q11.2DS group (with only part of the individuals
presenting high levels of dysfunctional beliefs),
which may be attributable to the fact that dysfunc-
tional beliefs in adolescents at risk are not as
strongly established as in adults. Nevertheless, even
in the absence of significant group differences, our
results indicate that the severity of dysfunctional
beliefs is closely related to the presence of paranoid
and negative, but not cognitive-perceptual symp-
toms. Even if both types of dysfunctional beliefs
(negative performance beliefs and need for
approval) were associated with paranoid and nega-
tive symptoms, our data suggested that the severity
of negative performance beliefs was the most
important predictor. This finding is consistent with
our hypothesis and several findings in the
literature.30–34 Based on the existing literature, the
association between negative performance beliefs
and paranoid symptoms was not expected.
However, it should be noted that two subscales (sus-
piciousness and social anxiety) of the SPQ load both
on the paranoid and negative dimensions in the
four-factor model used in our study,37 which may
partly explain the common findings for these two
dimensions. Furthermore, studies examining the
factorial structure of schizotypal symptoms have
consistently observed that suspiciousness and para-
noid ideations load both on the positive and the
negative dimensions.52,53 This may indicate that
shared mechanisms are involved in the develop-
ment of paranoid and negative symptoms.
Should these first results receive further confir-
mation in longitudinal studies, intervention strat-
egies focusing on negative performance beliefs may
be helpful to decrease the severity and/or prevent
the emergence of negative and paranoid symptoms
Negative symptoms in 22q11.2DS
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in patients with 22q11.2DS. According to
Perivoliotis and Cather, identifying the patients’
goals and subdividing them into smaller, concrete
and manageable subgoals is a beneficial strategy to
reduce the severity of negative performance
beliefs.54 Grant et al. reported that an 18-month CBT
focused on dysfunctional beliefs management was
effective in reducing the severity of negative symp-
toms in a group of low-functioning patients with
schizophrenia.55 This type of intervention is worth
considering in individuals with 22q11.2DS and
severe negative symptoms.
In accordance with the proposition formulated by
Rector et al., the present study also aimed at exam-
ining whether specific cognitive deficits were
related to the severity of negative performance
beliefs and negative symptoms in individuals with
22q11.2DS.27 Unsurprisingly, group comparisons
revealed the presence of widespread cognitive defi-
cits in participants with 22q11.2DS, which is
consistent with many previous findings.56–59 A
larger effect size was found for face recognition defi-
cits, adding further evidence that basic social
cognitive mechanisms are particularly affected in
22q11.2DS.60 Interestingly, face recognition deficit
was not only associated with the severity of negative
performance beliefs but also with the paranoid and
negative dimensions of the SPQ. Furthermore, our
data indicated that negative performance beliefs
significantly mediated the relationship between
face recognition and paranoid/negative symptoms.
Face recognition is an essential cognitive process
involved in the development of adapted social
skills.59 It may be the case that individuals facing
difficulties in this area are particularly prone to
experiencing unrewarding social interactions,
which may trigger the development and mainte-
nance of negative performance beliefs and ulti-
mately increase the risk of developing negative and
paranoid symptoms. However, this interpretation
remains speculative at this stage and requires
further confirmation, especially from longitudinal
studies.
The results of this study should be interpreted in
the light of the following limitations. Although the
results obtained using the SPQ were broadly con-
sistent with previous findings obtained with clinical
interviews, no direct comparison was performed
between these twomethods. This should be done in
future studies in order to better examine the reliabil-
ity of this evaluation tool in adolescent and young
adults with 22q11.2DS. Furthermore, the use of a
cross-sectional design did not allow investigating
the causal relationships between the studied vari-
ables. Specifically, it is still to be determined
whether negative performance beliefs play a causal
role in the development of negative symptoms or if
they appear as a consequence of them. We are cur-
rently performing longitudinal evaluations of this
cohort to overcome this issue. Third, the cognitive
battery used in the present study examined only
broad cognitive processes that have low ecological
validity. This may partly explain why several cogni-
tive domains were not associated with negative
symptoms and negative performance beliefs.
Fourth, the sample size was limited so that the
observed results should be replicated in independ-
ent samples. Finally, our control group was hetero-
geneous because it was composed of siblings and
community controls. In addition, no genetic testing
was performed on controls to exclude the presence
of the 22q11.2DS. Nevertheless, the probability
that one of the controls was affected by 22q11.2DS
is extremely low, given that strict exclusion
criteria were applied for the recruitment of these
participants.
In conclusion, this study is one of the first to
explore potential psychological mechanisms
involved in the development and maintenance of
negative symptoms in individuals with 22q11.2DS.
If future studies confirm the important role of nega-
tive performance beliefs and social cognition in the
clinical expression of negative and paranoid symp-
toms, this may help in the development of new
intervention strategies adapted for individuals with
22q11.2DS.
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